Such sophisticated design could enable a tumor-specific targeted delivery of the conjugate to PD-L1 expressing tumor cells with the guidance of PPA1, as well as the controlled release of DOX to acidic tumor tissues due to the cleavage of acid-sensitive linker, thus reducing the toxicity of DOX to non-tumor tissues. This evidence concerns the gene CD274 and neoplasm.